Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Slides:

Advertisements

Similar presentations

Allogeneic Transplant Following Brentuximab Vedotin Treatment in Patients with Relapsed or Refractory CD30+ Lymphomas Illidge T et al. Proc ASH 2011;Abstract.

Advertisements

Gopal AK et al. Proc ASH 2013;Abstract 4382.

Moskowitz CH et al. Proc ASH 2014;Abstract 290.

Brown JR et al. Proc ASH 2013;Abstract 523.

Phase 1/2 Study of Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Combination with Lenalidomide and Dexamethasone in Patients with Previously.

Efficacy and Safety of Three Bortezomib-Based Combinations in Elderly, Newly Diagnosed Multiple Myeloma Patients: Results from All Randomized Patients.

1Coiffier B et al. Proc ASH 2010;Abstract 114.

Palumbo A et al. Proc ASH 2012;Abstract 446.

Carfilzomib: High Single-Agent Response Rate with Minimal Neuropathy Even in High-Risk Patients 1 Baseline Peripheral Neuropathy Does Not Impact the Efficacy.

LaCasce A et al. Proc ASH 2014;Abstract 293.

Results of a Phase II Trial of Brentuximab Vedotin as First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT Chen RW et al. Proc ASH 2014;Abstract.

1 Baz R et al. Proc ASH 2014;Abstract Lacy MQ et al.

Efficacy of Denileukin Diftitox Retreatment in Patients with Cutaneous T-Cell Lymphoma Who Relapsed After Initial Response 1 Identification of an Active,

A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results in Patients with DLBCL.

Treatment with Bendamustine- Bortezomib-Dexamethasone in Relapsed/Refractory Multiple Myeloma Shows Significant Activity and Is Well Tolerated Ludwig H.

Interim Results of an International, Multicenter, Phase 2 Study of Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory.

FDG-PET Adapted Sequential Therapy with Brentuximab Vedotin and Augmented ICE Followed by Autologous Stem Cell Transplant for Relapsed and Refractory Hodgkin.

Frontline Therapy with Brentuximab Vedotin Combined with ABVD or AVD in Patients with Newly Diagnosed Advanced Stage Hodgkin Lymphoma Younes A et al. Proc.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma (MM) Patients: Initial Results of a Multicenter, Open Label.

A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Updated.

R-CHOP vs R-FC Followed by Maintenance with Rituximab vs Interferon-Alfa in Elderly Patients with Mantle Cell Lymphoma Kluin-Nelemans HC et al. Proc ASH.

Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) for Relapsed/Refractory Hodgkin Lymphoma (HL) in the Brentuximab.

Viardot A et al. Proc ASH 2014;Abstract 4460.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

A Phase II Study with Carfilzomib, Cyclophosphamide and Dexamethasone (CCd) for Newly Diagnosed Multiple Myeloma Bringhen S et al. Proc ASH 2013;Abstract.

Brentuximab Vedotin (SGN-35) Enables Successful Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma.

Ruan J et al. Proc ASH 2013;Abstract 247.

Updated Results of a Phase I First-in-Human Study of the BCL-2 Inhibitor ABT-199 (GDC-0199) in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic.

Dyer MJS et al. Proc ASH 2014;Abstract 1743.

Locatelli F et al. Proc ASH 2013;Abstract 4378.

Brentuximab Vedotin Administered Concurrently with Multi-Agent Chemotherapy as Frontline Treatment of ALCL and Other CD30-Positive Mature T-Cell and NK-Cell.

A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.

A Phase 2 Study of Single-Agent Brentuximab Vedotin for Front- Line Therapy of Hodgkin Lymphoma in Patients Age 60 Years and Above: Interim Results Yasenchak.

An Open-Label, Randomized Study of Bendamustine and Rituximab (BR) Compared with Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab,

Lenalidomide Maintenance After Stem-Cell Transplantation for Multiple Myeloma: Follow-Up Analysis of the IFM Trial Attal M et al. Proc ASH 2013;Abstract.

Moskowitz CH et al. Proc ASH 2014;Abstract 673.

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib:

Brentuximab Vedotin in Combination with RCHOP as Front-Line Therapy in Patients with DLBCL: Interim Results from a Phase 2 Study Yasenchak CA et al. Proc.

Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma: Final Results of the Phase Ib/II Ro-CHOP Study Dupuis J et al. Proc ASH.

Pomalidomide + Low-Dose Dexamethasone (POM + LoDex) vs High-Dose Dexamethasone (HiDex) in Relapsed/Refractory Multiple Myeloma (RRMM): MM-003 Analysis.

Results from the International, Randomized Phase 3 Study of Ibrutinib versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM)1.

Moskowitz CH et al. Proc ASH 2015;Abstract 182.

Palumbo A et al. Proc ASH 2012;Abstract 200.

Shustov AR et al. Proc ASH 2010;Abstract 961.

Nivolumab in Patients (Pts) with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Clinical Outcomes from Extended Follow-up of a Phase 1 Study.

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Oki Y et al. Proc ASH 2013;Abstract 252.

Vahdat L et al. Proc SABCS 2012;Abstract P

KEYNOTE-087: Pembrolizumab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma New Findings in Hematology: Independent Conference Coverage.

Mateos MV et al. Proc ASH 2013;Abstract 403.

San Miguel JF et al. 1 Proc EHA 2013;Abstract S1151.

Goede V et al. Proc ASH 2014;Abstract 3327.

Kahl BS et al. Proc ASH 2011;Abstract LBA-6.

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

Attal M et al. Proc ASCO 2010;Abstract 8018.

Fowler NH et al. Proc ASCO 2010;Abstract 8036.

Niesvizky R et al. Proc ASH 2010;Abstract 619.

Jakubowiak AJ et al. Proc ASH 2010;Abstract 862.

Coiffier B et al. Proc ASH 2010;Abstract 857.

Ansell SM et al. Proc ASH 2012;Abstract 798.

Final Results of a Frontline Phase 1/2 Study of Carfilzomib, Lenalidomide, and Low-Dose Dexamethasone (CRd) in Multiple Myeloma (MM)1 Final Results from.

Vitolo U et al. Proc ASH 2011;Abstract 777.

Faderl S et al. Proc ASCO 2011;Abstract 6503.

Seymour JF et al. Proc ASH 2013;Abstract 872.

Zaja F et al. Proc ASH 2010;Abstract 966.

Ahmadi T et al. Proc ASH 2011;Abstract 266.

Pomalidomide plus Low-Dose Dexamethasone in Myeloma Refractory to Both Bortezomib and Lenalidomide: Comparison of Two Dosing Strategies in Dual-Refractory.

Advani RH et al. Proc ASH 2011;Abstract 443.

Presentation transcript:

Forero-Torres A et al. Proc ASH 2011;Abstract 3711. Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL) Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Background Brentuximab vedotin (B-vedotin), an anti-CD30 antibody drug conjugate, induced a high rate of remission in 2 recent trials of patients with relapsed/refractory CD30+ lymphomas. Patients with HL: Complete remission (CR) rate = 34%, median duration of response in patients with CR = 20.5 mo (Proc ASCO 2011;Abstract 8031) Patients with sALCL: CR rate = 57%, median duration of response in patients with CR = 13.2 mo (Proc ASCO 2011;Abstract 8032) In both of these trials, a maximum of 16 cycles of B-vedotin was permitted (a median of 10 cycles for HL and 7 cycles for sALCL). Current Analysis Objective: To present a retrospective analysis of a subset of patients who received prolonged treatment (>16 cycles) with B-vedotin in a treatment extension study. Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Retrospective Analysis Eligibility (n = 15) Relapsed/refractory HL or sALCL Received 16 cycles of B-vedotin in a previous study Continued B-vedotin until disease progression, unacceptable toxicity or consent withdrawal Median number of treatment cycles = 19 (range: 17-29) Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Baseline Characteristics (Abstract Only) Relapsed/refractory HL 10 Relapsed/refractory sALCL 5 Median age 35 years Median number of prior therapies 3 (range 1-14) Failed previous autologous stem cell transplant (SCT) 9* * Two of these patients also failed allogeneic SCT Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Best Clinical Responses for Extended B-Vedotin Therapy (Abstract Only) CR* 73.3% Partial remission (PR) 13.3% Stable disease Median time from first dose to achievement of CR was 12 weeks (range: 5.4 to 48.9). Median duration of objective response has not been reached (range: 6.5+ to 21.8+ months). Fourteen patients were alive and free of documented disease progression at time of analysis. Median progression-free survival had not been reached (range: 11.8+ to 23.0+ months). * Includes all patients with sALCL (n = 5) Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Adverse Events (Abstract Only) Adverse events (in ≥30% of patients) All grades (n = 15) Peripheral sensory neuropathy (PSN)* 73% Fatigue 53% Upper respiratory tract infection Cough 40% Alopecia 33% Diarrhea Neutropenia† Pyrexia * Resolved or improved in 7/13 patients with a median time to resolution or improvement of 3.1 weeks (range 0.1-8); no Grade 3 or 4 PSN events observed † Only adverse event that occurred for the first time after cycle 16 in >1 patient (n = 2) Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Author Conclusions Patients with relapsed/refractory HL or sALCL exhibited favorable responses to extended treatment with B-vedotin. Duration of response (11 CRs and 2 PRs) ranged from 6.5+ to 21.8+ months, with 13 patients still receiving treatment. The safety profile of B-vedotin did not change significantly with treatment beyond 16 cycles, with most adverse events being mild. Forero-Torres A et al. Proc ASH 2011;Abstract 3711.

Investigator Commentary: Prolonged Treatment with Brentuximab Vedotin in Relapsed/Refractory HL or sALCL This is a retrospective analysis of a subset of patients with HL or sALCL who were treated with B-vedotin until disease progression or unacceptable toxicity. Interestingly, no additional toxicity was observed in patients receiving extended maintenance with B-vedotin. So if you had a patient who was either not eligible for a transplant or who did not want a transplant, you could administer this agent indefinitely. The fear is that the patient could experience chronic severe neuropathy with indefinite use, but that didn’t happen. Most patients on the study had Grade 1 or 2 neuropathy. In my experience with this agent, I’ve observed little Grade 3 and 4 neuropathy. Grade 2 neuropathy is reversible, so my strategy is to delay treatment for a week. Once it resolves to Grade 1, I reduce the dose and continue. A Phase III study (AETHERA trial) is currently evaluating the efficacy and safety of B-vedotin in patients at high risk of residual HL following autologous stem cell transplant. I’ve placed about 15 patients on this study and thus far it’s been difficult to discern who is receiving B-vedotin versus placebo. Interview with Craig Moskowitz, MD, January 11, 2012